Sovaprevir
Sovaprevir is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor. Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012.